FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376959665> ?p ?o ?g. }

• W4376959665 endingPage "e0285850" @default.
• W4376959665 startingPage "e0285850" @default.
• W4376959665 abstract "Anorexia is experienced by most people with lung cancer during the course of their disease and treatment. Anorexia reduces response to chemotherapy and the ability of patients to cope with, and complete their treatment leading to greater morbidity, poorer prognosis and outcomes. Despite the significant importance of cancer-related anorexia, current therapies are limited, have marginal benefits and unwarranted side effects. In this multi-site, randomised, double blind, placebo controlled, phase II trial, participants will be randomly assigned (1:1) to receive once-daily oral dosing of 100mg of anamorelin HCl or matched placebo for 12 weeks. Participants can then opt into an extension phase to receive blinded intervention for another 12 weeks (weeks 13-24) at the same dose and frequency. Adults (≥18 years) with small cell lung cancer (SCLC); newly diagnosed with planned systemic therapy OR with first recurrence of disease following a documented disease-free interval ≥6 months, AND with anorexia (i.e., ≤ 37 points on the 12-item Functional Assessment of Anorexia Cachexia Treatment (FAACT A/CS) scale) will be invited to participate. Primary outcomes are safety, desirability and feasibility outcomes related to participant recruitment, adherence to interventions, and completion of study tools to inform the design of a robust Phase III effectiveness trial. Secondary outcomes are the effects of study interventions on body weight and composition, functional status, nutritional intake, biochemistry, fatigue, harms, survival and quality of life. Primary and secondary efficacy analysis will be conducted at 12 weeks. Additional exploratory efficacy and safety analyses will also be conducted at 24 weeks to collect data over longer treatment duration. The feasibility of economic evaluations in Phase III trial will be assessed, including the indicative costs and benefits of anamorelin for SCLC to the healthcare system and society, the choice of methods for data collection and the future evaluation design. Trial registration. The trial has been registered with the Australian New Zealand Clinical Trials Registry [ACTRN12622000129785] and approved by the South Western Sydney Local Health District Human Research Ethics Committee [2021/ETH11339]. https://clin.larvol.com/trial-detail/ACTRN12622000129785." @default.
• W4376959665 created "2023-05-18" @default.
• W4376959665 creator A5000949291 @default.
• W4376959665 creator A5007993808 @default.
• W4376959665 creator A5008487561 @default.
• W4376959665 creator A5009024319 @default.
• W4376959665 creator A5024052979 @default.
• W4376959665 creator A5034942769 @default.
• W4376959665 creator A5039366110 @default.
• W4376959665 creator A5044211124 @default.
• W4376959665 creator A5054414906 @default.
• W4376959665 creator A5054485095 @default.
• W4376959665 creator A5059680031 @default.
• W4376959665 creator A5064514171 @default.
• W4376959665 creator A5065203569 @default.
• W4376959665 creator A5072329463 @default.
• W4376959665 creator A5074740633 @default.
• W4376959665 creator A5078379938 @default.
• W4376959665 creator A5085121805 @default.
• W4376959665 date "2023-05-17" @default.
• W4376959665 modified "2023-09-30" @default.
• W4376959665 title "Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial)" @default.
• W4376959665 cites W1986071902 @default.
• W4376959665 cites W1990166011 @default.
• W4376959665 cites W2000445173 @default.
• W4376959665 cites W2018963739 @default.
• W4376959665 cites W2019607817 @default.
• W4376959665 cites W2023008186 @default.
• W4376959665 cites W2024558179 @default.
• W4376959665 cites W2046387692 @default.
• W4376959665 cites W2055864845 @default.
• W4376959665 cites W2056141471 @default.
• W4376959665 cites W2057044110 @default.
• W4376959665 cites W2059614742 @default.
• W4376959665 cites W2063931484 @default.
• W4376959665 cites W2080159858 @default.
• W4376959665 cites W2082494913 @default.
• W4376959665 cites W2127260850 @default.
• W4376959665 cites W2132309748 @default.
• W4376959665 cites W2135367382 @default.
• W4376959665 cites W2138452959 @default.
• W4376959665 cites W2140452679 @default.
• W4376959665 cites W2148287035 @default.
• W4376959665 cites W2169423683 @default.
• W4376959665 cites W2213935416 @default.
• W4376959665 cites W2278001291 @default.
• W4376959665 cites W2530172016 @default.
• W4376959665 cites W2587612112 @default.
• W4376959665 cites W2593128963 @default.
• W4376959665 cites W2611376562 @default.
• W4376959665 cites W2777415032 @default.
• W4376959665 cites W2886411259 @default.
• W4376959665 cites W2896970133 @default.
• W4376959665 cites W2915732899 @default.
• W4376959665 cites W2930210278 @default.
• W4376959665 cites W3115452618 @default.
• W4376959665 cites W4210487975 @default.
• W4376959665 cites W752571875 @default.
• W4376959665 doi "https://doi.org/10.1371/journal.pone.0285850" @default.
• W4376959665 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37195996" @default.
• W4376959665 hasPublicationYear "2023" @default.
• W4376959665 type Work @default.
• W4376959665 citedByCount "0" @default.
• W4376959665 crossrefType "journal-article" @default.
• W4376959665 hasAuthorship W4376959665A5000949291 @default.
• W4376959665 hasAuthorship W4376959665A5007993808 @default.
• W4376959665 hasAuthorship W4376959665A5008487561 @default.
• W4376959665 hasAuthorship W4376959665A5009024319 @default.
• W4376959665 hasAuthorship W4376959665A5024052979 @default.
• W4376959665 hasAuthorship W4376959665A5034942769 @default.
• W4376959665 hasAuthorship W4376959665A5039366110 @default.
• W4376959665 hasAuthorship W4376959665A5044211124 @default.
• W4376959665 hasAuthorship W4376959665A5054414906 @default.
• W4376959665 hasAuthorship W4376959665A5054485095 @default.
• W4376959665 hasAuthorship W4376959665A5059680031 @default.
• W4376959665 hasAuthorship W4376959665A5064514171 @default.
• W4376959665 hasAuthorship W4376959665A5065203569 @default.
• W4376959665 hasAuthorship W4376959665A5072329463 @default.
• W4376959665 hasAuthorship W4376959665A5074740633 @default.
• W4376959665 hasAuthorship W4376959665A5078379938 @default.
• W4376959665 hasAuthorship W4376959665A5085121805 @default.
• W4376959665 hasBestOaLocation W43769596651 @default.
• W4376959665 hasConcept C118552586 @default.
• W4376959665 hasConcept C121608353 @default.
• W4376959665 hasConcept C126322002 @default.
• W4376959665 hasConcept C142724271 @default.
• W4376959665 hasConcept C159110408 @default.
• W4376959665 hasConcept C1862650 @default.
• W4376959665 hasConcept C197934379 @default.
• W4376959665 hasConcept C204787440 @default.
• W4376959665 hasConcept C27081682 @default.
• W4376959665 hasConcept C27415008 @default.
• W4376959665 hasConcept C2777288759 @default.
• W4376959665 hasConcept C2777704314 @default.
• W4376959665 hasConcept C2778654693 @default.
• W4376959665 hasConcept C2779951463 @default.
• W4376959665 hasConcept C535046627 @default.
• W4376959665 hasConcept C71924100 @default.

• next